复方苦参注射液对癌性胸水CA125指标影响的临床观察

Clincial Observation on Level of CA125 in Pleuural Effusion of Lung Cancer with Compound Kusen Injection

目的：观察复方苦参注射液对肺癌恶性胸水CA125指标影响的临床疗效。方法：免疫发光法监测血清、胸水中肿瘤标志物全套（CEA、AFP、CA125、CA153、CA199）含量。秩和检验比较胸水中CA125在复方苦参注射液灌注胸腔前后的变化。结果：血清与胸水中肿瘤标志物指标阳性率一致（100%）。胸水肿瘤标志物指标含量是血清中的1~3倍以上。经复方苦参注射液胸腔灌注治疗后胸水中CA125指标含量明显低于治疗前（P〈0.01）。结论：复方苦参注射液有降低肺癌恶性胸水中CA125指标含量的作用,提示其在一定程度上有控制癌性胸水生长速度的作用。

Objective： To observe the level of cancer antigen 125（ CA125） in malignant pleuural effusion for lung cancer with the Compound Kusen Injection. Methods： Tumor makers indexes in serum and pleural effusion were monitored by Immunoassay test Method. The rank sum test was used to compare the change of CA125 in pleural effusion before and after Compound Kusen Injection perfusing the chest. Results： Positive rate of Tumor makers in serum was the same as that in pleural effusion（ 100%）. Tomor makers in pleural effusion were more 1 to 3 times than that in serum. Index of CA125 in pleural effusion was obviously lower after Compound Kusen Injection perfusing the chest（ P 0. 01）. Conclusion： CA125 in pleural effusion for lung cancer was decresed by Compound Kusen Injection perfusing the chest. It suggests that Compound Kusen Injection controls the speed of growth of pleuural effusion for lung cancer in some quantity.